Literature DB >> 7998837

Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression.

N Y Jin1, S Funahashi, H Shida.   

Abstract

We devised vaccinia virus (VV)-based vector systems that support higher levels of expression of cloned genes in the early and late phases of the infection cycle than reported previously. Enhanced expression can be obtained by combining the promoter of the A-type inclusion body protein gene, the mutated early region of the 7.5-kDa gene promoter (7.5-kDa promoter), and the promoter of the hemagglutinin (HA) gene. One construct produced 60 micrograms/10(6) cells of chloramphenicol acetyltransferase (CAT), equivalent to 10-18% of total cell protein. Another construct produced about seven times more CAT during the early phase than the amount synthesized under the control of the 7.5-kDa promoter alone. The envelope proteins of human immunodeficiency virus type I synthesized during the early phase of infection were more active as immunogens than these proteins synthesized during the late phase, regardless of the amounts produced.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998837     DOI: 10.1007/BF01379134

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  28 in total

1.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

2.  Structure of vaccinia virus early promoters.

Authors:  A J Davison; B Moss
Journal:  J Mol Biol       Date:  1989-12-20       Impact factor: 5.469

3.  Biogenesis of poxviruses: relationship between a translation complex and formation of A-type inclusions.

Authors:  Y Ichihashi; S Dales
Journal:  Virology       Date:  1973-02       Impact factor: 3.616

4.  Expression of envelope glycoproteins of human immunodeficiency virus by an insect virus vector.

Authors:  S I Hu; S G Kosowski; K F Schaaf
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

5.  Production of human alpha-interferon in silkworm using a baculovirus vector.

Authors:  S Maeda; T Kawai; M Obinata; H Fujiwara; T Horiuchi; Y Saeki; Y Sato; M Furusawa
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

6.  A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells.

Authors:  D D Patel; C A Ray; R P Drucker; D J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  P L Earl; R W Doms; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

9.  Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.

Authors:  J Klaniecki; T Dykers; B Travis; R Schmitt; M Wain; A Watson; P Sridhar; J McClure; B Morein; J T Ulrich
Journal:  AIDS Res Hum Retroviruses       Date:  1991-10       Impact factor: 2.205

10.  Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.

Authors:  H Shida; T Tochikura; T Sato; T Konno; K Hirayoshi; M Seki; Y Ito; M Hatanaka; Y Hinuma; M Sugimoto
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  8 in total

1.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.

Authors:  T Murakami; T Y Zhang; Y Koyanagi; Y Tanaka; J Kim; Y Suzuki; S Minoguchi; H Tamamura; M Waki; A Matsumoto; N Fujii; H Shida; J A Hoxie; S C Peiper; N Yamamoto
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

4.  Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions.

Authors:  Y Suzuki; Y Koyanagi; Y Tanaka; T Murakami; N Misawa; N Maeda; T Kimura; H Shida; J A Hoxie; W A O'Brien; N Yamamoto
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm.

Authors:  Xianfeng Zhang; Tomoyoshi Sobue; Mao Isshiki; Shun-ichi Makino; Makoto Inoue; Kazunori Kato; Tatsuo Shioda; Takashi Ohashi; Hirotaka Sato; Jun Komano; Hideji Hanabusa; Hisatoshi Shida
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

6.  A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.

Authors:  Sonia T Wennier; Kay Brinkmann; Charlotte Steinhäußer; Nicole Mayländer; Claudia Mnich; Ursula Wielert; Ulrike Dirmeier; Jürgen Hausmann; Paul Chaplin; Robin Steigerwald
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

7.  SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus.

Authors:  Masahiro Kitabatake; Shingo Inoue; Fumihiko Yasui; Shoji Yokochi; Masaaki Arai; Kouichi Morita; Hisatoshi Shida; Minoru Kidokoro; Fukashi Murai; Mai Quynh Le; Kyosuke Mizuno; Kouji Matsushima; Michinori Kohara
Journal:  Vaccine       Date:  2006-09-11       Impact factor: 3.641

Review 8.  Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.

Authors:  Minoru Kidokoro; Hisatoshi Shida
Journal:  Vaccines (Basel)       Date:  2014-10-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.